Real-world effectiveness and tolerability are important when selecting glucose-lowering therapy in T2DM. A prospective, multicenter observational study in Bangladesh evaluated a fixed-dose combination of empagliflozin 10 mg and linagliptin 5 mg in adults with T2DM receiving the regimen either alone or with other antidiabetic therapies. Glycemic parameters, BMI, blood pressure, renal function, and adverse events were monitored over three months.

A total of 822 adults were included. Mean HbA1c decreased from 9.13% to 8.18% in the fixed-dose combination alone group and from 10.20% to 8.12% in those receiving combination therapy with additional agents (p<0.001). Significant reductions were also observed in fasting and post-prandial blood glucose (p<0.001). BMI declined from 26.81 kg/m² to 25.90 kg/m² (p=0.008). Systolic and diastolic blood pressure decreased by 11.09 mmHg and 4.41 mmHg, respectively (p<0.001). Estimated glomerular filtration rate remained stable.
Adverse events were uncommon, with hypoglycemia reported in 10.95%, genital mycotic infections in 3.04%, and urinary tract infections in 2.80%.

These findings indicate that the fixed-dose combination of empagliflozin and linagliptin improves short-term glycemic control, weight-related parameters, and blood pressure with acceptable safety in individuals with T2DM. Extended follow-up may help confirm durability of response and long-term safety in broader clinical populations.